These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22292717)

  • 21. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of statins in hypertriglyceridemia.
    Stein EA; Lane M; Laskarzewski P
    Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
    Wassmann S; Laufs U; Bäumer AT; Müller K; Ahlbory K; Linz W; Itter G; Rösen R; Böhm M; Nickenig G
    Hypertension; 2001 Jun; 37(6):1450-7. PubMed ID: 11408394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
    Passi S; Stancato A; Aleo E; Dmitrieva A; Littarru GP
    Biofactors; 2003; 18(1-4):113-24. PubMed ID: 14695926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
    Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
    Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T; Yamazaki H; Suzuki H; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
    Bell RM; Yellon DM
    J Am Coll Cardiol; 2003 Feb; 41(3):508-15. PubMed ID: 12575984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
    Malinowski JM
    Am J Health Syst Pharm; 1998 Nov; 55(21):2253-67; quiz 2302-3. PubMed ID: 9825877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.
    Suzuki T; Nozawa T; Sobajima M; Igarashi N; Matsuki A; Fujii N; Inoue H
    Int Heart J; 2008 Jul; 49(4):423-33. PubMed ID: 18753726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
    Liu W; Li WM; Gao C; Sun NL
    J Autoimmun; 2005 Dec; 25(4):258-63. PubMed ID: 16242301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP; Wheeler DC; Chong CC;
    Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
    Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
    Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex.
    de Oliveira CV; Funck VR; Pereira LM; Grigoletto J; Rambo LM; Ribeiro LR; Royes LF; Furian AF; Oliveira MS
    Pharmacol Res; 2013 May; 71():1-8. PubMed ID: 23428346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
    Cunningham SM; Rush JE; Freeman LM
    J Vet Intern Med; 2013; 27(4):985-9. PubMed ID: 23758137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin.
    Johnston TP; Baker JC; Hall D; Jamal S; Palmer WK; Emeson EE
    Atherosclerosis; 2000 Apr; 149(2):303-13. PubMed ID: 10729380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.